Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled multiple-dose study of VX-809 in adults with cystic fibrosis homozygous for F508del-CFTR
2008-006446-25Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-809 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2009; status: completed.
02
Drugs
lumacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2008-006446-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006446-25.